MYC and triple-negative breast carcinoma: Notably, the N-8 compound exhibited the most significant activity and demonstrated a high degree of selectivity for the G4 structure of the c-MYC gene, presenting itself as a promising candidate for a novel therapy for triple-negative breast cancer.